- Discussion
- 10.1038/s41433-025-04070-z
The effect of ethnicity on the accuracy of fundal reflex referrals.
- Oct 11, 2025
- Eye (London, England)
- Yutao Du + 2 more +2
Publications from 2021 to 2026
Showing 10 of 110 papers
The effect of ethnicity on the accuracy of fundal reflex referrals.
Prevalence of chemsex and sexualized drug use among men who have sex with men: A systematic review and meta-analysis.
A Systematic Review: Efficacy of Different Intraocular Pressure-Lowering Agents in Black Individuals
Glaucoma is one of the leading causes of blindness worldwide, with the Black population experiencing an earlier onset and severe form of the disease compared to the White population. Despite the increased prevalence in the Black community, most research pertaining to glaucoma is focused on White patients. The current management guidelines recommend prostaglandin analogues and non-selective beta-adrenergic antagonists as the mainstay treatment, however their comparative efficacy in the Black community has not been thoroughly investigated.This systematic review aims to investigate the efficacy of the various intraocular pressure (IOP) lowering agents used to treat primary open angle glaucoma (POAG) and ocular hypertension (OHT) in Black patients.A systematic review of three randomised controlled trials was conducted to assess the efficacy of IOP-lowering agents specifically in the Black population. The protocol was set prior to the literature search and registered in PROSPERO (CRD420025652374). Databases searched included PubMed, Cochrane Library, Europe PMC and Semantic Scholar. Two independent researchers reviewed the articles and data was extracted from the three eligible articles. Risk of bias was assessed using the Risk of Bias (RoB) 2 tool.Our study found prostaglandin analogues to be highly efficient in the Black community and non-selective beta-adrenergic antagonists to have a lower efficacy in this population. The results align with the current National Institute for Health and Care Excellence (NICE) guidelines recommending prostaglandin analogue as the first-line treatment for POAG and OHT. However, the NICE guidelines recommend non-selective beta-adrenergic antagonists as the second-line treatment, which has a lower efficacy in Black patients. In addition, our study found prostamides to be only slightly less efficient compared to prostaglandin analogues in the Black population.In conclusion, prostaglandin analogues are a suitable first-line IOP-lowering agent in Black patients. Further research is required to investigate a suitable second-line treatment option in this community if patients have any adverse effects or do not tolerate the first-line option or need additional reduction in IOP.
Read moreP-668 Assessing the role of artificial intelligence in identifying the optimal embryo for transfer: a systematic review and meta-analysis
Abstract Study question Can AI-based models reliably predict IVF outcomes by evaluating embryo quality? Summary answer The majority of AI-based models demonstrated high performance in predicting live birth, clinical pregnancy, and embryo ploidy status. What is known already Ensuring precision in embryo assessment is vital for optimizing IVF outcomes, yet traditional methods relying on human judgment remain subjective and introduce interobserver variability. Emerging AI-driven models integrating clinical, demographic, and laboratory data, beyond morphological and morphokinetics data, offer a more objective and comprehensive approach to evaluating embryo potential. Study design, size, duration A systematic review and meta-analysis building upon previous research, incorporating 21 studies published from 2022 onward. This continuation expands the evidence base on AI-driven prediction models in IVF/ICSI cycles, focusing on preimplantation embryos deemed suitable for transfer. The input data is diverse, incorporating demographics data, clinical and laboratory records, morphokinetics and morphological data. The primary outcomes assessed include the predictive performance for live birth, clinical pregnancy, and embryo ploidy status. Participants/materials, setting, methods A systematic literature search was conducted in the PubMed/Medline, Embase, and Web of Science databases, restricted to articles published in English up to January 2025. To ensure continuity with the previous meta-analysis, only studies published from 2022 onward were considered. The initial search identified 1319 studies, of which 57 were duplicates and 1241 were excluded for not meeting the inclusion criteria. After full-text screening and citation mining, 21 studies were deemed eligible for inclusion. Main results and the role of chance For live birth prediction, pooled sensitivity and specificity were 83% (95% CI: 71–90%) and 87% (95% CI: 59–97%), with PPV and NPV of 88% (95% CI: 48–98%) and 82% (95% CI: 76–87%). Clinical pregnancy prediction showed sensitivity of 80% (95% CI: 68–88%), specificity of 78% (95% CI: 69–85%), PPV of 80% (95% CI: 68–88%), and NPV of 72% (95% CI: 67–77%). For embryo ploidy, sensitivity and specificity were 74% (95% CI: 71–78%) and 73% (95% CI: 68–79%), with PPV and NPV both at 74%. Pooled estimates across all outcomes showed sensitivity of 74% (95% CI: 69–79%), specificity of 77% (95% CI: 72–82%), PPV of 78% (95% CI: 70–84%), and NPV of 74% (95% CI: 69–79%). The Area Under the Curve (AUC) of the Summary Receiver Operating Characteristics (SROC) curve was 0.809, and the partial AUC (pAUC) was 0.648, demonstrating consistent and reliable predictive performance across outcomes. Limitations, reasons for caution The limited number of studies meeting the inclusion criteria and the diverse designs used in developing AI models, which can increase heterogeneity, serve as limitations. Including women of all ages is another constraint, as advanced maternal age is linked to reduced IVF success rates. Wider implications of the findings The performance metrics suggest robust predictive capabilities of AI-based models in assisted reproduction. The latest results keep underscoring the potential of AI to complement traditional embryo evaluation methods, providing objective and reliable predictions for IVF outcomes. More research and increased collaboration among developers are essential for further improvements. Trial registration number No
Read moreCross-protection of meningococcal B vaccines against gonorrhea: A systematic review and Meta-analysis.
Phase 3, Randomized, Comparison Study of Intracameral Bimatoprost Implant 10 µg and Selective Laser Trabeculoplasty.
To evaluate the intraocular pressure (IOP)-lowering effect and safety of up to 2 bimatoprost implant administrations versus selective laser trabeculoplasty (SLT). Phase 3 (Stage 2), randomized, 24-month, multicenter, patient- and efficacy evaluator-masked, paired-eye clinical trial (NCT02507687). Patients (n = 183) with open-angle glaucoma or ocular hypertension inadequately managed with topical IOP-lowering medication for reasons other than efficacy. Patients received a single 360° SLT procedure in 1 eye and 10-µg bimatoprost implant administration in the contralateral eye. Initially, implant-treated eyes received a second implant at week 16 if safety criteria were met. After a protocol amendment, implant-treated eyes were retreated with flexible scheduling if IOP was >17 mm Hg and safety criteria were met. The primary efficacy variable was IOP change from baseline, with primary timepoints at weeks 4, 12, and 24. Safety measures included treatment-emergent adverse events (TEAEs) and ocular safety measures. Mean (±SE) baseline IOP (mm Hg) was 25.2 ± 0.22 and 25.1 ± 0.22 in implant- and SLT-treated eyes, respectively. Least-squares mean (±SE) IOP reduction from baseline (mm Hg) for eyes treated with up to 2 implants versus SLT was 6.8 ± 0.28 versus 6.2 ± 0.28 at week 4, 6.9 ± 0.30 versus 6.4 ± 0.30 at week 12, and 6.9 ± 0.27 versus 6.5 ± 0.28 at week 24. The probability of not having required nonstudy (rescue) IOP-lowering treatment at days 360 and 720, respectively, was 67.5% and 50.2% for implant-treated eyes versus 68.7% and 60.6% for SLT-treated eyes. The most common ocular TEAE in both implant- and SLT-treated eyes was increased IOP attributed to wearing off of efficacy. Mean (±SE) percentage change in corneal endothelial cell density from baseline at month 24 was -6.2 ± 1.13% in implant-treated eyes (-7.9 ± 2.04% with fixed readministration; -5.2 ± 1.35% with flexible readministration) versus -3.1 ± 0.43% in SLT-treated eyes. The bimatoprost implant demonstrated statistical and clinical noninferiority to SLT in IOP reduction from baseline at weeks 4, 12, and 24. In subgroup analysis, patients with flexible implant readministration met the same criteria. Both the implant and SLT demonstrated sustained (2-year) IOP lowering in many eyes. A flexible administration schedule improved the safety profile of the implant over the fixed administration schedule.
Read moreA Retrospective Quantitative Analysis of the Shared Care Glaucoma Scheme (SCGS) in Monitoring Glaucoma Progression During COVID-19.
This study aimed to investigate the impact of the shared care glaucoma scheme (SCGS), implemented during COVID-19 due to reduced clinic space and lockdown measures, on glaucoma disease progression in patients. The study was conducted between January 2021 and December 2023 and explored joint care provided by ophthalmologists and community optometrists in Lothian. Data collected include patient demographics, intraocular pressure (IOP) readings, mean deviation visual field scores (MDVFs), a history of interventions during the pre-SCGS phase, glaucoma medications, and referrals to Princess Alexandra Eye Pavilion (PAEP). The IOP, MDVF, and glaucoma medications were collected at three stages: pre-SCGS, SCGS, and post-SCGS. The Glauc-Strat-Fast tool was used to assign each patient a pre-SCGS glaucoma stage. A total of 172 patients (85 males, 49.4%) participated in this study, with a mean age of 77.7 years (SD = 10.4). Sixteen patients (9.30%) were referred to PAEP during the scheme; the Redgroup of patients, identified using the Glauc-Strat-Fast tool, represented five of these referrals (31.3%). Four of the referred patients (25%) had an intervention at PAEP, either a change in medication or a surgical procedure. There was no significant increase in the IOP values from the pre-SCGS phase to the post-SCGS phase. The MDVF values had a mean deterioration of 0.5998 dB from the pre-SCGS phase to the post-SCGS phase. Overall, disease stability was maintained in all glaucoma subgroups. The study, therefore, suggests the possibility of implementing the SCGS in the United Kingdom as part of routine glaucoma service in the post-COVID-19 era.
Read moreMicrovascular Complications
This chapter focuses on diabetic retinopathy, diabetic kidney disease (DKD) and diabetic neuropathy. Diabetic retinopathy is a microvascular complication of diabetes. The screening programme has been an effective population-level intervention. Since its implementation around 20 years ago, there has been a reduction in the vision impairment due to diabetic eye disease. With the progression of DKD and renal function decline, a number of recognised complications can occur, such as anaemia, mineral bone disorder, metabolic acidosis and fluid retention. The chapter summarises the current tests that are available for the diagnosis of diabetic neuropathy. Diabetic neuropathy lacks a targeted pharmaceutical intervention, underscoring the pivotal role of stringent glycaemic control as a primary management strategy. Additionally, diabetic neuropathy can potentially result in foot ulcers and, in severe cases, may necessitate amputations. In the management of neuropathic pain, pharmacotherapy assumes a prominent role. Concurrently, lifestyle modifications play a crucial role in pain management.
Read moreIs intravitreal faricimab an effective treatment for diabetic macular oedema not‐responsive to aflibercept? An audit of treated patients at the Princess Alexandra eye pavilion
Aims/Purpose: We aim to evaluate both functional and anatomical outcomes of patients switched from aflibercept to faricimab for management of treatment‐resistant diabetic macular oedema (DMO) in a real‐world environment, and the proportion of patients who achieved improvement, stability or deterioration.Methods: Casenotes of 20 eyes not responding to aflibercept, then switched to faricimab were reviewed. Patient demographics, best‐corrected visual acuity (BCVA) and presence of macular oedema on OCT pre‐switch and at post‐treatment clinic review, and injection intervals were recorded. We then categorised whether there was an improvement, stability or deterioration in both BCVA and presence of macular oedema on OCT.Results: Of 16 eyes where analysis was complete for BCVA, there was improvement in 31% (n = 5), stability in 19% (n = 3) and deterioration in 50% (n = 8). Of the eyes where there was deterioration, 4 had other co‐morbidity which affected BCVA. Of 17 eyes with pre‐ and post‐switch macular OCT, there was improvement in macular oedema in 71% (n = 12), stability in 24% (n = 4) and deterioration in 6% (n = 1). The mean injection interval where prescribed 4x 1 monthly (n = 13) was 61 days, with a range from 35 ‐ 138 days.Conclusions: In this real‐world setting with challenges providing patients with regular monthly treatment, faricimab demonstrates the ability to improve DMO in chronic disease with sub‐optimal dosing regimens. A majority of patients demonstrated anatomical improvements, and functional stability or improvement was seen in half of treated eyes. Though the anatomical outcomes were more positive than the functional outcomes on BCVA, this likely reflects the chronicity of DMO in affected eyes, and notably in half of the eyes treated where BCVA deteriorated, there was an alternative cause for this. Given the poorer prognosis of treatment non‐responsive DMO, faricimab is promising as a further option for these harder to treat patients. Overall, there would appear to be a role for faricimab to be a treatment option in chronic‐DMO, and its increased durability is beneficial in busy centres where it is challenging to provide patients with 1‐monthly dosing. This could be further supported by investigating outcomes in patients with treatment‐naive disease.
Read moreCorrection: Intraocular pressure, primary open-angle glaucoma and the risk of retinal vein occlusion: a Mendelian randomization mediation analysis
The first and last name of the author Hansjörg Baurecht were unfortunately interchanged. The original article has been corrected.
Read more